Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune disease affecting the movement apparatus, accompanied by skin manifestations of various severity in most cases. In the last decade, the treatment of PsA has been enriched by many new therapeuticals specifically aiming at anti inflammatory molecules altering the immune system, e.g. tumor necrosis factor alpha or many interleukins.
Ixekizumab is a monoclonal antibody against interleukin 17A, which has showed its effectiveness and safety in the treatment of psoriasis. SPIRIT 1 and SPIRIT 2 trials have proved the good effect and satisfactory safety profile of ixekizumab in the population of PsA patients.